When do biologic drug patents expire and when will biosimilars launch?

Comprehensive claims and US patent landscape analysis for U.S. Patent 10,028,935 (antioxidant/ROS-modulating therapeutic methods)

Executive summary: U.S. Patent 10,028,935 claims broad, method-of-treatment coverage for administering Formula I or Formula II compounds to subjects with diseases or insults characterized by reduced antioxidant levels and/or increased oxygen radical generation. The claim set is structured to (1) sweep broadly across therapeutic areas via an expansive disease list and (2) narrow to a defined chemical series through two Markush-style formula scaffolds and enumerated compound embodiments. From a freedom-to-operate and litigation stance, enforceability centers on claim construction of the “reduced antioxidant levels and/or increased oxygen radical generation” disease association language, scope of Formula I/II Markush variables (including optional/variable substituents), and whether competitors’ candidates fall within the literal chemical scope or are limited by prosecution history estoppel. The practical risk for potential licensees is that the patent is drafted as a platform-style “ROS/antioxidant deficiency” method with wide therapeutic coverage, so generic or substitute chemistry work must show design-around both at the compound-structure level and at the mechanistic/disease-association framing.

What is U.S. Patent 10,028,935 claiming and how broad is claim 1?

Short answer: Claim 1 is a method-of-treatment claim that covers administering therapeutically effective amounts of defined Formula I compounds (or salts) to treat a disease/injury/condition associated with reduced antioxidant levels and/or increased oxygen radical generation. It is broad in therapeutic area and broad in disease “association,” but constrained by the chemical scope of Formula I.

Claim 1 architecture (what drives breadth)

Claim 1 has three load-bearing components:

Indication framing by pathophysiology
- “a disease, injury, or condition, associated with reduced antioxidant levels and/or increased oxygen radical generation”
- This is not limited to a biomarker assay or a specific validated threshold. It reads like a mechanistic category that can attach to many common conditions (inflammation, ischemia-reperfusion injury, hemolysis, toxic exposure, etc.).
Administration method
- “comprising administering to a subject… a therapeutically effective amount”
- No dosing regimen, route, formulation, or treatment duration is recited in the independent claim as provided. That increases infringement surface area for any route/formulation that includes administration of a covered compound.
Compound restriction by Markush Formula I
- Variables R, R1/R2/R3, L, L1/L2, R4/R5/R6/R7/R8, and integers m/n/p/w define a family of related structures.
- The claim then includes dependent claim 6 listing specific compounds, which can act as embodiments for construction but are not the sole gate.

Is claim 1 “mechanism-of-action” limited or “use-label broad”?

The language ties the covered patient population to conditions “associated with” antioxidant reduction and/or ROS generation. That is broader than a strict requirement to measure a biomarker, but narrower than “any disease.” In litigation, the more difficult question is what “associated with” means during claim construction:

It can be argued as a generalized medical knowledge linkage.
Or it can be argued as requiring an actual causal/functional relationship between the claimed condition and ROS/antioxidant status.

The drafting includes an expansive dependent disease list in claims 2-5, which signals the patent’s intended construction as broad, not assay-limited.

Which diseases and injuries are covered by the dependent claims in U.S. Patent 10,028,935?

Short answer: Dependent claims 2-5 and 7-11 enumerate a wide therapeutic universe, including cardiovascular, neurologic, liver, inflammatory, infectious, renal, metabolic, ocular, reproductive, seizure, sepsis, stroke, hemolysis, toxic shock, and a large “traumatic insult” category including bioweapon exposure and drug overdoses.

Dependent claims 2-5 (Claim 1 → claim 2 narrowing via disease list)

Claim 2 specifies the disease/injury/condition categories:

Cardiovascular disease; cerebral palsy
Liver disease; cystic fibrosis
Dementia
Inflammatory disease
Amyotrophic lateral sclerosis
Acute respiratory distress syndrome
Infectious disease
Lupus
Eye disorder
Multiple sclerosis
Kidney disease
Neuropathy
Encephalopathy
Diabetes
Beta thalassemia; sickle cell disease
Parkinson’s disease
Pulmonary fibrosis
Reproductive disease; infertility
Seizure disorder
Sepsis
Stroke
Gangrene; toxic shock; spontaneous hemolysis
Hemolysis induced by chemical agents
Traumatic insult

Claim 3 further specifies cardiovascular subtypes and inflammatory subtypes:

Cardiovascular: atherosclerosis, myocardial infarction, COPD, chronic heart failure
Inflammatory: inflammatory bowel disease, Crohn’s disease, rheumatoid arthritis, colitis
Liver: cirrhosis, hepatitis
Chemical-agent hemolysis: anti-malarial treatment, chemotherapy treatment
Eye: cataracts, macular degeneration

Claim 4 expands “traumatic insult” to many exposure/clinical situations:

Bioweapons; chemical/heat burns
Contrast-induced nephropathy
Drug overdose; radiation exposure
Cigarette smoke; toxic gas
Blast injury; contact sensitivity; delayed hypersensitivity
Insults causing hearing loss, envenomation, sunburn, transplant rejection, gunshot, compression injury, toxicodendrin-species inflammation, skin damage
Chemotherapy treatment

Claim 5 narrows to specific bioweapons and specific overdose agents:

Bioweapons: ricin, Bacillus anthracis, ebola virus, Clostridium botulinum, nipah virus
Drug overdose: acetaminophen or morphine

Dependent claims 7-11 replicate the same disease architecture

Claims 7-11 mirror claims 2-6 in the context of claim 6 embodiments and do not materially narrow therapeutic scope; they primarily anchor the Markush scaffold to enumerated compound sets.

Implication for competitors: The disease list helps the patentee argue broad “association” rather than claim-limiting assay requirements. For design-around, the safer strategy is structural non-infringement, not indication restriction.

How do the enumerated compounds in claim 6 narrow or strengthen infringement arguments?

Short answer: Claim 6 provides a non-exhaustive list of specific Formula I embodiments. Enumerated examples can strengthen infringement arguments because defendants must either avoid those exact structures or show they still fall outside the Markush ranges.

Practical effect of the claim 6 list

The long enumerated list includes multiple stereochemical variants (S/R), functional groups (carboxylic acids, esters, acylated side chains), and different imidazole substitution patterns (e.g., 1H-imidazol-5-yl with substituents at the imidazole side). This indicates the Markush formula is intended to cover several closely related analogs.

Litigation leverage:

If a defendant’s compound matches one of the enumerated structures, the patentee has a straightforward “literal match” path.
If it is not identical, the patentee will push for broad reading of the variable ranges (m/n/p/w and R substituents) to bring the compound within the Formula I literal scope.

What compounds are protected under Formula II in claims 12-17, and how does it differ from Formula I?

Short answer: Claim 12 defines a second Markush scaffold (Formula II) with similar pathophysiology framing but changed variable set, including R9 and a slightly different set of allowed substituent types. Claims 17 and onward list specific Formula II embodiments.

Claim 12 variables and what they suggest about scope

Compared to Formula I, Formula II:

Includes R9: H, C1-6 alkyl, or C(=O)C1-6 alkyl
Maintains L/L1/L2 and the amino/acyl/heteroatom motifs and similar ranges for m/n/p/w

Implication: Formula II likely covers a distinct structural subset while keeping the same method coverage. That means a competitor design-around may have to clear both families if their candidate sits near the boundary of Formula I vs II.

Claim 17 enumerated Formula II embodiments

Claim 17 lists specific quaternary-like amino acid/imidazole conjugates with trimethyl quaternization and acetoxy/propionyloxy variants:

(2R)-4-(2-acetamido-2-carboxyethylthio)-2-hydroxy-N,N,N-trimethyl-4-oxobutan-1-aminium
and analogs with amino side chains and acylated ester substituents (acetoxy/propionyloxy)

Implication: These look like closely related prodrug or salt/ester variants of an imidazole-containing thioether system. If competitor chemistry uses ester masking or quaternary moieties, it increases overlap risk.

Which method claims overlap across claims 1-5 vs 12-22? Is this a single invention split into two formula families?

Short answer: Yes, the patent appears to split its coverage into two independent method families: Formula I (claims 1-11, with nested dependent claims 2-5 and compound embodiments in claim 6) and Formula II (claims 12-22, with disease parallels and compound embodiments in claim 17). The disease/injury taxonomy is duplicated.

Overlap mapping (high-level)

Claim 1: Formula I + method
Claims 2-5: disease list, including traumatic insults and specific bioweapons/overdose agents
Claim 6: Formula I compound embodiments
Claim 12: Formula II + method
Claims 13-16: identical disease list and same bioweapon/overdose narrowing
Claim 17: Formula II compound embodiments
Claims 18-22: mirrored dependent disease subcategories

Litigation impact: If a defendant argues non-infringement by contesting Formula I, the patentee can shift to Formula II depending on structural proximity. This reduces “single-point” invalidity or non-infringement leverage.

How strong is the patent estate’s patentability position based on claim style (Markush + disease list)?

Short answer: The claims read as a broad method framework tethered to structural Markush chemical series. That can be strong for infringement reach but can face classic Markush enablement/definiteness and written description challenges in some jurisdictions if prior art exists and breadth is not supported by examples.

Definitional risks and construction pressure points

Key claim construction issues likely to be litigated:

“associated with reduced antioxidant levels and/or increased oxygen radical generation”
- Is it a functional limitation tied to the compound’s effect, or a disease-characterizing property?
- For infringement, does the patentee need to show that the treated disease inherently has this association?
“therapeutically effective amount”
- Typical method language that courts treat as functional.
- Non-infringement can be sought by arguing lack of therapeutic effect for the specific condition, but the claim does not tie effect to specific doses or measured outcomes.
Markush ranges and optional substituents
- Variables include optional groups at multiple positions. Literal infringement analysis may be sensitive to how a court interprets the Markush permutations.

Practical enforcement profile

The disease list is expansive and helps the patentee argue practical utility and broad coverage intent.
The compound enumeration helps demonstrate that breadth is not purely abstract; the patentee has specific examples of covered chemistry.

Net: enforcement reach is high, but claim construction and factual disputes about “association” and coverage boundaries can become central.

What patent litigation risks exist for competitors developing ROS/antioxidant therapies?

Short answer: High risk if (a) the candidate molecule matches the Formula I/II chemical boundaries and (b) the intended use aligns with the claimed disease list or any disease argued to be “associated” with ROS/antioxidant deficiency.

Where defendants typically fight

Structural non-infringement
- Narrow reading of substituent scope and geometry (R/S stereochemistry; thiol/thioether linkages; ester vs acid presence).
Claim construction
- Push for restrictive interpretation of “associated with” and whether it requires a specific mechanistic relationship.
Validity defenses
- Written description and enablement for the full Markush breadth.
- Obviousness versus prior art antioxidant/ROS modulators (especially if the chemical series overlaps known thiol/imidazole or imidazole-thioether antioxidant scaffolds).

Settlement dynamics to expect

Given platform-style broad claims spanning many indications and even bioweapons countermeasures, settlements often cover multiple indication labels, not just one therapeutic area, unless the competitor can demonstrate a clear non-overlap in chemistry.

What would a generic entry or biosimilar-style risk look like for a method-of-treatment patent?

Short answer: “Generic” manufacturing itself does not bypass method-of-treatment claims. If the compound is generic and still administered for covered diseases using covered chemistry, the method claim is still a direct infringement target.

If the active compound is small-molecule

A generic applicant must ensure that its use does not infringe method claims. Label carveouts are common.
If the generic is intended for indications that fall inside claims 2-5/13-16, design-around via labeling may be necessary.

If the active is marketed for multiple indications

A company can be exposed if any covered use triggers the claimed method.
Carrier versions (salts, esters, prodrugs) still may infringe if they fall within “pharmaceutically acceptable salt” or within the Markush formulas.

Orange Book status and FDA regulatory entry: what matters for infringement exposure?

Short answer: The regulatory pathway does not extinguish method-of-treatment exposure. But Orange Book and labeling control the real-world infringement map: the indications and routes included in approved labeling can determine whether physicians can prescribe covered uses without triggering litigation.

Because the provided input does not include the patent’s listed reference drug(s), application number(s), or FDA Orange Book listings, the only actionable point is structural: the patent is drafted as a broad method claim that can attach to any approved use that fits the claimed disease-injury categories.

Key comparisons: how Formula I vs Formula II changes the design-around geometry

Short answer: Formula I and Formula II define two closely related compound families, and the disease framing is the same. A competitor must clear whichever formula family their lead falls under.

Comparison table: scope levers

Dimension	Formula I (claims 1-11)	Formula II (claims 12-22)	Design-around implication
Primary limitation	Compound of Formula I	Compound of Formula II	Avoid both scaffolds or ensure compound lies outside both literal variable sets
Variable set	R, R1/R2/R3; L/L1/L2; R4-R8	Similar, plus R9 substitution options	Differences in R9 type can be decisive for borderline structures
Disease coverage	Same broad list via dependent claims	Same broad list via dependent claims	Label limitation alone may not avoid infringement if “association” is argued broadly
Listed embodiments	Claim 6 long list (S/R stereochem + acid/ester variants)	Claim 17 trimethyl quaternized embodiments + acetoxy/propionyloxy	If competitor’s candidate resembles these listed embodiments, literal infringement risk rises

Claims 1-22 also act like a “countermeasure platform”: what are the commercialization and licensing implications?

Short answer: The inclusion of bioweapon exposures and overdose agents suggests the patentee targeted government/public-health programs and broad-use procurement. Licensing strategies typically seek category control rather than narrow single-indication exclusivity.

Licensing exposure logic

If a competitor wants to market for ROS/antioxidant-linked indications across multiple organ systems, it may need a license covering the platform method.
If the competitor focuses on indications outside the list, the “associated with” phrase can still be used to argue infringement for additional indications.

Key Takeaways

U.S. Patent 10,028,935 is a broad method-of-treatment patent that ties therapeutic administration to diseases/injuries “associated with reduced antioxidant levels and/or increased oxygen radical generation,” using two chemical Markush families (Formula I and Formula II).
Dependent claims expand coverage across a long disease list and a broad traumatic insult category, including specific bioweapons and acetaminophen or morphine overdoses.
The enumerated compound embodiments in claims 6 and 17 strengthen infringement pathways by supplying concrete covered structures, while the Markush variables preserve wide literal scope.
For competitors, the highest risk is structural overlap with either Formula I or Formula II. Label carveouts may be insufficient if “association” is construed broadly.
The patent is enforcement-friendly in reach because it lacks dosing/route/formulation constraints in the independent claim as provided, making most administration forms of covered chemistry plausible infringement candidates.

FAQs

What does “associated with reduced antioxidant levels and/or increased oxygen radical generation” require for infringement?
It functions as an indication/patient-population limitation rather than a strict assay-threshold requirement, and is supported by the dependent disease list.
Do ester and salt forms avoid infringement for U.S. Patent 10,028,935?
Not if they fall within “pharmaceutically acceptable salt” and within the Formula I/II structural variable scope, including listed acid/ester embodiments.
Can a competitor avoid infringement by restricting labeling to non-enumerated indications?
Not reliably, because the independent claim is not limited to only the enumerated diseases; it covers any disease/injury “associated with” the antioxidant/ROS framing.
Is Formula II a separate invention or a continuation of the same method?
It is a parallel method family with the same therapeutic framing but a different compound scaffold through a separate Markush formula and enumerated embodiments.
What is the fastest litigation target: compound non-infringement or claim construction of the ROS/antioxidant association?
Compound non-infringement is typically first-line, because chemical scope is defined by Markush variables; claim construction is the next lever if the compound is near the boundary.

References

US Patent 10,028,935 (claims text as provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	November 12, 1998	10,028,935	2037-01-31
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,028,935

Summary for Patent: 10,028,935